1. Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis
- Author
-
Yanqing Gong, Liqun Zhou, Jianrong Zheng, Shuyuan Guo, Anbang He, Jieshan Chi, Xinliang Zhong, Yonghao Zhan, Zhicong Chen, and Xuesong Li
- Subjects
95%CI, 95% Confidence interval ,0301 basic medicine ,Oncology ,ROC curve, receiver operating characteristic curve ,NMIBC, non-muscle-invasive bladder cancer ,Urologic cancer ,T, size or direct extent of the primary tumour ,TRIPOD, Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis ,TCGA-PRAD, prostate adenocarcinoma in TCGA chort ,Metastasis ,TCGA-BLCA, bladder cancer in TCGA chort ,Prostate cancer ,0302 clinical medicine ,miRNA, microRNA ,FFPE, formalin fixed paraffin-embedded ,Medicine ,CHN, Chinese ,GEO, Gene Expression Omnibus ,TCGA-KICH, kidney chromophobe carcinoma in TCGA chort ,DM, distant metastasis ,TCGA-KIRP, kidney papillary cell carcinoma in TCGA chort ,Hazard ratio ,OR, odds ratios ,qRT-PCR, quantitative real-time polymerase chain reaction ,REMARK, Reporting Recommendations for Tumour Marker Prognostic Studies ,General Medicine ,G, histology grade ,Prognosis ,BRISQ, Biospecimen Reporting for Improved Study Quality ,AT, advanced T-stage ,Prostate-specific antigen ,030220 oncology & carcinogenesis ,miRNAs ,HG, higher histologic grade ,qPCR, quantitative polymerase chain reaction ,RFS, relapse free survival ,Research Paper ,LNM, lymph nodes metastasis ,Stage, TNM stage ,ISH, in-situ hybridization ,miRNA panel ,Urologic Neoplasms ,medicine.medical_specialty ,BCa, bladder cancer ,PCa, prostate cancer ,Gleason, gleason score ,WHO, World Health Organization ,General Biochemistry, Genetics and Molecular Biology ,OS, overall survival ,03 medical and health sciences ,Bioinformatics analysis ,TCGA-KIRC, kidney clear cell carcinoma in TCGA chort ,Internal medicine ,Humans ,Progression-free survival ,IQR, interquartile range ,non-CHN, Non-Chinese ,Bladder cancer ,BCR-FS, biochemical recurrence free survival ,SE, standard error ,CSS, cancer/disease specific survival ,business.industry ,AS, advanced TNM stage ,KCa, kidney cancer ,Biomarker ,Odds ratio ,medicine.disease ,PRISMA, Preferred Reporting Items for Systematic Review and Meta-analysis ,DFS, disease free survival ,MicroRNAs ,PSA, prostate specific antigen ,030104 developmental biology ,NOS, Newcastle-Ottawa quality assessment scale ,AUC, the area under the curve ,HR, Hazard Ratio ,PFS, progression free survival ,RNA, ribonucleic acid ,TCGA, The Cancer Genome Atlas ,business ,Kidney cancer - Abstract
Background MicroRNAs(miRNAs) are involved in the formation, maintenance, and metastasis of urologic cancer. Here, we aim to gather and evaluate all of the evidence regarding the potential role of miRNAs as novel predictors of urologic cancer survival. Methods A systematic review was performed to identify and score all of the published studies that evaluated the prognostic effects of miRNAs in kidney (KCa), bladder (BCa) or prostate cancer (PCa). Where appropriate, the summary effects of miRNAs on urologic cancer were meta-analysed. The reliability of those results was then further validated by an integrated analysis of the TCGA cohort and miRNA panel. Results Of 151 datasets, 80 miRNAs were enrolled in this systematic review. A meta-analysis of the prognostic qualities of each miRNA identified an objective association between miRNA and prognosis. miR-21 was identified as an unfavourable miRNA with the overall survival (HR:2.699, 1.76–4.14, P
- Published
- 2018
- Full Text
- View/download PDF